Longview congratulates Antag Therapeutics on closing its €80 million Series A financing to advance its novel Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist therapy into the clinic for obesity. Longview invests in select portfolio companies of Broadview Ventures Inc, and we’re excited to be participating in this financing in support of the Antag team. We welcome Series A lead Versant Ventures and new investors SR One Management, Dawn Biopharma and Pictet Asset Management to a great syndicate including Novo Nordisk Holdings and Export and Investment Fund of Denmark. https://lnkd.in/eNPGa7ZM
Longview Ventures
Venture Capital and Private Equity Principals
Boston, Massachusetts 214 followers
Longview Ventures focuses on clinical-stage investments in cardiovascular disease and stroke.
About us
In 2018, the Leducq Trust launched Longview Ventures to make investments in select portfolio companies of Broadview Ventures, a mission-driven investment organization focused on cardiovascular disease and stroke. Longview focuses on clinical-stage companies, Series B – Series C, as a complement to Broadview’s continued dedication to Seed and Series A financings.
- Website
-
https://broadviewventures.org/longview-ventures/
External link for Longview Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- Boston, Massachusetts
- Type
- Nonprofit
- Founded
- 2018
Locations
-
Primary
Get directions
265 Franklin St
Boston, Massachusetts 02110, US
Employees at Longview Ventures
-
Maria Berkman, MD, MBA
MedTech VC Broadview Ventures | Longview Ventures
-
Tom Needham
Director, Head of BioPharma, Broadview Ventures Inc
-
Nichole Neal
Director of Operations at Broadview Ventures Inc.
-
David Prim, PhD
Principal at Broadview Ventures | Biomedical Engineer | Interested in funding, transactions, and strategy for life science companies, esp…
Updates
-
Longview congratulates XII Medical on closing its Series B financing to continue advancement of its truly novel neuromodulation therapy to treat obstructive sleep apnea. Longview invests in select portfolio companies of Broadview Ventures Inc, and we’re excited to continue supporting XII's great team, led by Garrett Schwab, Anthony Caparso, and Anthony Natale, M.D.. We welcome Series B lead Omega Funds and new investor Intuitive Ventures to a great syndicate including Cleveland Clinic Innovations, Ajax Health, Aperture Venture Partners, JobsOhio Growth Capital Fund, and CincyTech.
We welcome our lead investor Omega Funds and new investor Intuitive Ventures, and are grateful to our existing investors including founding investor Cleveland Clinic Innovations, Ajax Health, Broadview Ventures Inc, Longview Ventures, Aperture Venture Partners, JobsOhio Growth Capital Fund, CincyTech and our unnamed strategic investor. Saoussen Ben Halima, PhD Claudio Nessi Marla Jalbut, MD, MBA Murielle Thinard McLane Jotthe Kannappan Vijay Rajasekhar, MD, MBA Vivian Emmely Golfin, MD JD Friedland Zach Eisen Duke Rohlen Aftab Kherani Doug Koo Shane Kreidel Daniel Gottlieb Maria Berkman, MD Anthony Natale, M.D. Eric S. Tatyana Hower Steph Ison Samuel Lee, MD, MBA Ashley Keating Anthony Caparso John Sam Bhavesh Patel Rabih Nassif Andrew Wu
XII MEDICAL RAISES $45 MILLION IN SERIES B FINANCING TO ADVANCE BEST-IN-CLASS NEUROMODULATION THERAPY FOR OBSTRUCTIVE SLEEP APNEA
prnewswire.com
-
Longview congratulates AtaCor Medical, Inc. on closing its $28 million Series C financing. Longview invests in select portfolio companies of Broadview Ventures Inc, and we’re excited to be participating in this financing in support of the AtaCor team. Arboretum Ventures, Hatteras Venture Partners, Catalyst Health Ventures, BayMed Venture Partners, Rick Sanghera https://lnkd.in/evfGB3Kq
We are excited to announce that we have successfully closed $28M in our Series C financing round. Funding from this round will support regulatory submissions for our temporary pacing platform and the pilot study for our third generation EV-ICD lead system. Congrats to the entire AtaCor team on this important milestone! Read the full announcement here (https://lnkd.in/gBP7ji6j). #atacor #cardiology #CRM @HRS #EV-ICD
-
-
Longview congratulates Basking Biosciences Inc on closing its $55 million financing. Longview invests in select portfolio companies of Broadview Ventures Inc, and we’re excited to be participating in this financing in support of the Basking team. ARCH Venture Partners Insight Partners Solas BioVentures RTW Investments, LP Rev1 Ventures The Ohio State University
Today marks an exciting milestone at Basking: We announced the close of our $55m financing, led by ARCH Venture Partners, plus participation from additional new investors Insight Partners, Platanus, Solas BioVentures and RTW Investments, LP, as well as existing investors Longview Ventures, Rev1 Ventures and The Ohio State University. Thank you to our team, investors and advisors. #AIS #stroke #drugdevelopment #financing #clinicalresearch https://lnkd.in/eUZNkeup
-
-
Longview congratulates Comanche Biopharma on closing its $75 million Series B financing! Longview invests in select portfolio companies of Broadview Ventures Inc, and we’re excited to be participating in this financing in support of the Comanche team.
We’re thrilled to announce the closing of an oversubscribed $75 million Series B financing. This capital investment by a top-tier syndicate will enable us to advance our mission to develop and make globally available the first treatment targeting a root cause of preeclampsia: over-production of the protein sFlt1 by the placenta. Existing investors GV (Google Ventures), F-Prime Capital, Lilly Asia Ventures 礼来亚洲基金, and Longview Healthcare Ventures participated in the Series B round, joined by new investors New Enterprise Associates (NEA), who led the round, and Atlas Venture. Concurrent with the Series B raise, Scott Gottlieb, M.D., Partner at NEA and former Commissioner of the FDA, and David Grayzel, M.D., Partner at Atlas Venture, have joined our Board of Directors. Read our press release to learn more about the extraordinary, complex unmet needs in preeclampsia, and our breakthrough science and drug candidate, CBP-4888, to potentially deliver a solution: https://bit.ly/425OlVc #preeclampsia #maternalhealth #pregnancy #siRNA #RNA
-